Seock‐Ah Im
Seoul National University · 1,730 works · 85,074 citations · h-index 110
Top works
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- Palbociclib and Letrozole in Advanced Breast Cancer
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer